Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Bioventus Inc.BVS · Entity 4996 | SVP & General Counsel | April 10, 2026 | April 14, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Bioventus Inc.
Report date April 10, 2026 · Filed April 14, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Class A Common StockSEC Table I · non-derivative | Direct | 153,655 |
Ending reported balance
After 2026-04-10 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-04-10 · Exercise / conversion · Acquired 9,925 · Balance 157,967 Row 2 · 2026-04-10 · Tax withholding · Disposed 4,312 · Balance 153,655 |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 9,925 |
Reported balance
After 2026-04-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-04-10 · Exercise / conversion · Disposed 9,925 · Balance 9,925 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F2: The RSUs shall vest in four equal installments on each of the first four anniversaries of April 10, 2023, in each case subject to the Reporting Person continuing in service through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock.
F2: The RSUs shall vest in four equal installments on each of the first four anniversaries of April 10, 2023, in each case subject to the Reporting Person continuing in service through the applicable vesting date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 01, 2022 Filed Apr 6, 2022 01:16 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 37,476 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-013966 · doc4.xml · derivative · entry 3 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 37,476 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F4 · derivative.exercise_date: The RSUs vested on April 1, 2022. F4 · derivative.expiration_date: The RSUs vested on April 1, 2022. Read SEC document |
| April 01, 2022 Filed Apr 6, 2022 01:16 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 37,476 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-013966 · doc4.xml · nonDerivative · entry 1 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,148 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. Read SEC document |
| March 14, 2022 Filed Mar 17, 2023 01:21 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 35,545 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-008794 · doc4.xml · derivative · entry 3 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 35,545 Underlying: Class A Common Stock · 35,545 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of Class A common stock. F4 · derivative.exercise_date: The original grant of 35,545 RSUs vest in four approximately equal annual installments beginning on March 14, 2023. F4 · derivative.expiration_date: The original grant of 35,545 RSUs vest in four approximately equal annual installments beginning on March 14, 2023. Read SEC document |
| March 14, 2022 Filed Apr 13, 2023 01:03 UTC | Bioventus Inc. BVS · Entity 4996 | GrantStock Option (Right to Buy) · Derivative | 96,133 | $0.00 Strike: $12.66 | $0.00 |
DisclosureSEC source: 0001578563-23-000020 · primary_doc.xml · derivative · entry 2 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 96,133 Underlying: Class A Common Stock · 96,133 shares Expires 2032-03-14 F1 · derivative.exercise_date: The options shall vest in four equal installments on each of the first four anniversaries of March 14, 2022, in each case subject to the Reporting Person continuing in service through the applicable vesting date. Read SEC document |
| February 14, 2022 Filed Feb 16, 2022 02:31 UTC | Bioventus Inc. BVS · Entity 4996 | SaleClass A Common Stock | 1,294 | $11.99 | $15,512.86 |
DisclosureSEC source: 0000899243-22-006548 · doc4.xml · nonDerivative · entry 2 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,672 F2 · kind: Reflects shares sold to cover taxes upon the vesting of restricted stock units on February 11, 2022 pursuant to a standing 10b5-1 instruction. F3 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $11.9077 to $11.99, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 11, 2022 Filed Feb 16, 2022 02:31 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionRestricted Stock Units · Derivative | 4,400 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-006548 · doc4.xml · derivative · entry 3 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 4,400 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. F4 · derivative.exercise_date: The restricted stock units vested on February 11, 2022. F4 · derivative.expiration_date: The restricted stock units vested on February 11, 2022. Read SEC document |
| February 11, 2022 Filed Feb 16, 2022 02:31 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 4,400 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-006548 · doc4.xml · nonDerivative · entry 1 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 19,966 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. Read SEC document |
| February 10, 2022 Filed Feb 15, 2022 01:37 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionPhantom Profit Units · Derivative | 21,165 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-22-006329 · doc4.xml · derivative · entry 3 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Class A Common Stock · 21,165 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each Phantom Profit Unit represented a contingent right to receive one share of Class A common stock and vested on the one-year anniversary of the consummation of the Isuser's initial public offering. F1 · derivative.exercise_date: Each Phantom Profit Unit represented a contingent right to receive one share of Class A common stock and vested on the one-year anniversary of the consummation of the Isuser's initial public offering. F1 · derivative.expiration_date: Each Phantom Profit Unit represented a contingent right to receive one share of Class A common stock and vested on the one-year anniversary of the consummation of the Isuser's initial public offering. Read SEC document |
| February 10, 2022 Filed Feb 15, 2022 01:37 UTC | Bioventus Inc. BVS · Entity 4996 | Tax withholdingClass A Common Stock | 6,599 | $12.88 | $84,995.12 |
DisclosureSEC source: 0000899243-22-006329 · doc4.xml · nonDerivative · entry 2 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,566 Read SEC document |
| February 10, 2022 Filed Feb 15, 2022 01:37 UTC | Bioventus Inc. BVS · Entity 4996 | Exercise / conversionClass A Common Stock | 21,165 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000899243-22-006329 · doc4.xml · nonDerivative · entry 1 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,165 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each Phantom Profit Unit represented a contingent right to receive one share of Class A common stock and vested on the one-year anniversary of the consummation of the Isuser's initial public offering. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 20:37 UTC | Bioventus Inc. BVS · Entity 4996 | GrantStock Options · Derivative | 9,500 | $0.00 Strike: $15.23 | $0.00 |
DisclosureSEC source: 0000899243-21-014843 · doc4.xml · derivative · entry 3 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,500 Underlying: Class A Common Stock · 9,500 shares Expires 2031-03-31 F3 · derivative.exercise_date: The stock option vests in four equal annual installments beginning on April 1, 2022. Read SEC document |
| April 01, 2021 Filed Apr 5, 2021 20:37 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 37,476 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-014843 · doc4.xml · derivative · entry 2 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,476 Underlying: Class A Common Stock · 37,476 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest on April 1, 2022 and have no expiration date. F2 · derivative.expiration_date: The restricted stock units vest on April 1, 2022 and have no expiration date. Read SEC document |
| February 11, 2021 Filed Feb 16, 2021 23:08 UTC | Bioventus Inc. BVS · Entity 4996 | GrantRestricted Stock Units · Derivative | 4,400 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-21-006742 · doc4.xml · derivative · entry 1 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,400 Underlying: Class A Common Stock · 4,400 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit represents a contingent right to receive one share of Class A common stock. F2 · derivative.exercise_date: The restricted stock units vest on February 11, 2022. F2 · derivative.expiration_date: The restricted stock units vest on February 11, 2022. Read SEC document |
| February 11, 2021 Filed Apr 5, 2021 20:37 UTC | Bioventus Inc. BVS · Entity 4996 | PurchaseCommon Stock | 1,000 | $13.00 | $13,000.00 |
DisclosureSEC source: 0000899243-21-014843 · doc4.xml · nonDerivative · entry 1 D'Adamio Anthony · CIK 0001835184 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,000 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.